about
Substantial alterations of the cutaneous bacterial biota in psoriatic lesionsComparison of ustekinumab and etanercept for moderate-to-severe psoriasisThe treatment of psoriasis with etanercept.Folate supplementation during methotrexate therapy for patients with psoriasis.A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.Off-label dermatologic uses of anti-TNF-a therapies.Alefacept for the treatment of psoriasis and other dermatologic diseases.Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.Pharmacovigilance and biosimilars: considerations, needs and challenges.Treatment of atopic dermatitis in pregnancy.Interferon beta-1a-induced morphea.Item-level psychometric properties for a new patient-reported psoriasis symptom diary.Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.Cutaneous Bacillus anthracis infection.National Psoriasis Foundation clinical consensus on disease severity.No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.Ethical considerations when prescribing biologics in dermatology.Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled TrialSecukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.Successful treatment of plaque psoriasis with self-administered subcutaneous alefaceptA phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisAlefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyManagement of psoriasis in pregnancySimilar names for similar biologicsPractice gaps. Methotrexate-induced liver toxicity: replacing the liver biopsyNew Therapies for PsoriasisCore Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and AcceptanceSystematic review of the real-world evidence of adalimumab safety in psoriasis registriesDefining drug-free remission of skin disease in patients with plaque psoriasisComprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasisBenefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials
P50
Q21144280-590916B2-2186-4BA0-A1AF-5574087DF978Q28270369-CB483CE2-B4E7-41F4-B128-4EC1EAA8941DQ36131169-F3B8A444-197A-446E-A99C-3CDC6A86DB60Q36274253-05EBDCB4-B20A-4115-96D4-8AB82053C0F7Q36434758-66FBE1DA-463B-482C-AAA2-2758BABF9AB3Q36434813-11503FAD-1C8C-4C55-8A12-E7F161866445Q36478308-B96D6220-6398-4EB4-9A94-96DF29B989E1Q36986043-C46176CF-428E-49B5-B372-D76DD82362E5Q37457321-1373DBF4-3C08-4011-9A35-496C8F1B6A82Q37568378-172EAE73-F917-4058-BAC1-7ED2C936EE72Q37739573-9A23CED8-A106-4239-ABFC-BC71974F31A0Q38092850-279D0E1C-3840-42A4-8B9B-95719ED1519CQ38126535-CE5BEC53-5695-4657-A665-38CCBF9B3E7DQ39321058-1C5847AD-2BF1-4583-AA7C-FBFE1F51B96DQ39349136-51AC84D9-870C-4BFB-A117-647B5F7514AEQ42613896-81A17974-4EDD-402D-9B88-327E47A983C2Q43796769-B5984F58-6C5E-48B7-8F0D-B2663C9D849FQ44927235-E1DC1478-AA8F-4CE1-8E59-D5BFEC28650EQ47745642-0F2F27B5-4E40-4A71-8308-707046DF0EAAQ48266852-C4420211-C2A0-402C-94BE-6E53C7D1A359Q48399815-9B2473C4-3B8C-4942-B7F0-0008F8CA7CBDQ61990567-7077AF2E-D39B-40F6-83BA-31470D43615DQ64998959-1A7C1C21-7837-4891-9C67-804E5F8E29AFQ81645589-F3618E20-CFA7-4A4B-944D-EE42BF7236B8Q82100704-9DCAF348-8B5D-47FC-A014-9E9395E0DD71Q84911400-CAD57E3F-B296-45CA-BF81-0C597ADDD920Q87198481-2F9D0525-160E-43DB-B4D6-BD058102FD77Q87361149-C5DBEAE2-F410-49F2-807C-ADCAC112A6FEQ88156077-4EF74D31-BE6F-4E7F-BAF8-0BB1C5C40099Q88929608-CC3BD753-C84B-44E7-B990-3CC8E4BDC7ABQ89010555-F4DBF392-B248-4A9B-A154-C0A4ED587C8DQ90690977-90626BE2-23D6-4453-9597-28B2B6EF261CQ91203291-07EC8CA0-707E-4761-B461-D40D56AF3786Q91250534-5FC7967F-6EA0-407C-9797-9BFB3FDCB0FBQ91315164-27C5C7D9-F999-49EC-94DE-A40B913134BD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruce E Strober
@en
Bruce E Strober
@es
Bruce E Strober
@nl
Bruce E Strober
@sl
Bruce Strober
@fr
type
label
Bruce E Strober
@en
Bruce E Strober
@es
Bruce E Strober
@nl
Bruce E Strober
@sl
Bruce Strober
@fr
prefLabel
Bruce E Strober
@en
Bruce E Strober
@es
Bruce E Strober
@nl
Bruce E Strober
@sl
Bruce Strober
@fr
P106
P21
P31
P496
0000-0002-8394-2057